Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337461 | 0.84 | HTR2A (0.48) | HTR2AHTR2CKDM4EALDH1A1 | |
| SCHEMBL4212899 | 0.83 | KDM4E (0.46) | HTR2AHTR2CKDM4EALDH1A1 | |
| SCHEMBL4212724 | 0.83 | MAP4K4 (0.44) | GRM5ALDH1A1 | |
| SCHEMBL4204478 | 0.82 | HTR2C (0.63) | HTR2AHTR2CKDM4EALDH1A1 | |
| SCHEMBL4208588 | 0.81 | MAP4K4 (0.45) | HTR2AHTR2CGAAL3MBTL1ALDH1A1 | |
| SCHEMBL4005649 | 0.76 | HTR2C (0.58) | HTR2AHTR2CKDM4EALDH1A1 | |
| SCHEMBL4215873 | 0.75 | MAP4K4 (0.51) | ALDH1A1 | |
| SCHEMBL28935833 | 0.75 | GRM5 (0.37) | GRM5 | |
| Hydrochloric Acid SCHEMBL4206024 | 0.75 | HTR2C (0.57) | HTR2AHTR2CKDM4EALDH1A1 | |
| SCHEMBL4009889 | 0.74 | HTR2A (0.39) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| EP-2094695-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | Cascade Therapeutics Inc. (CA) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009079765-A1 | COMPOUNDS WITH ACTIVITY AT THE 5-HT2C RECEPTOR | CASCADE THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008009125-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885GRM5 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.